Видео ютуба по тегу Duvelisib

Duvelisib plus romidepsin in r/r PTCL
Duvelisib plus romidepsin in r/r PTCL
Dr. Flinn on the Mechanism of Action and Toxicity Profile of Duvelisib (IPI-145)
Dr. Flinn on the Mechanism of Action and Toxicity Profile of Duvelisib (IPI-145)
Duvelisib - Copiktra - All You Need to Know in 3 Minutes.
Duvelisib - Copiktra - All You Need to Know in 3 Minutes.
A Study of Duvelisib vs Ofatumumab in Relapsed/Refractory CLL
A Study of Duvelisib vs Ofatumumab in Relapsed/Refractory CLL
Duvelisib in CAR T-cell therapy for CLL
Duvelisib in CAR T-cell therapy for CLL
Oral time-limited duvelisib/venetoclax in R/R CLL
Oral time-limited duvelisib/venetoclax in R/R CLL
What is the role for idelalisib and duvelisib in CLL?
What is the role for idelalisib and duvelisib in CLL?
Duvelisib and FCR: a recipe for success in CLL
Duvelisib and FCR: a recipe for success in CLL
The DUO trial: dose modifications on response to duvelisib in patients with SLL/CLL
The DUO trial: dose modifications on response to duvelisib in patients with SLL/CLL
Duvelisib for COVID-19
Duvelisib for COVID-19
Update on PI3K inhibitors for CLL: Idelalisib, copanlisib, duvelisib, and umbralisib
Update on PI3K inhibitors for CLL: Idelalisib, copanlisib, duvelisib, and umbralisib
Dr. Leslie Discusses Duvelisib in Follicular Lymphoma
Dr. Leslie Discusses Duvelisib in Follicular Lymphoma
Safety profiles of idelalisib, duvelisib and TGR-1202 in treating CLL
Safety profiles of idelalisib, duvelisib and TGR-1202 in treating CLL
PRIMO: Optimising the dose of duvelisib in patients with R/R peripheral T-cell lymphoma
PRIMO: Optimising the dose of duvelisib in patients with R/R peripheral T-cell lymphoma
Duvelisib in Relapsed/Refractory CLL
Duvelisib in Relapsed/Refractory CLL
Duvelisib for R/R PTCL: updates from the PRIMO trial
Duvelisib for R/R PTCL: updates from the PRIMO trial
Duvelisib reduces CRS whilst maintaining CAR-T function
Duvelisib reduces CRS whilst maintaining CAR-T function